Future RCTs should evaluate the safety and efficacy of PPARα-targeted therapies, such as fenofibrate, as adjunctive treatments in HF, particularly in patients with metabolic comorbidities, including T2DM and HFpEF. Here, PPARA is linked to hydrops fetalis.